Related Experiment Video
Updated: May 28, 2026

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature
Michael Gnant1, Philippe Clézardin
1Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. michael.gnant@meduniwien.ac.at
Abstract:
The bone marrow microenvironment provides a site for cancer cells to evade systemic anticancer therapy. Dormant tumor micrometastases are believed to be the source of disease persistence and relapse; however, the exact characteristics of cancer stem cells vs. cancer cells with limited metastatic potential have yet to be elucidated. Bisphosphonates inhibit osteoclast-mediated bone resorption, are approved for treating malignant bone disease from advanced cancers, and have shown efficacy for preventing cancer treatment-induced bone loss. Altering the bone marrow microenvironment to make it less conducive to cancer cell survival is now emerging as an important means to prevent cancer recurrence. This review aims to distill the diverse literature and provide a brief overview of the numerous preclinical and early clinical studies of bisphosphonates demonstrating a variety of direct and indirect anticancer activities that affect both the tumor cell (the "seed") and surrounding microenvironment (the "soil"). Recently, zoledronic acid was found to improve disease-free survival and overall survival in some adjuvant breast cancer settings and prolonged survival in patients with multiple myeloma and other advanced cancers. In the prostate cancer setting, antiresorptive therapy was reported to delay the development of overt bone metastases. Ongoing studies will provide further insight regarding the anticancer potential of bisphosphonates and other antiresorptive agents.
Insights
Bisphosphonates, used to treat bone disease, show promise in preventing cancer recurrence by altering the bone marrow microenvironment. These agents exhibit direct and indirect anticancer effects, impacting both tumor cells and their surroundings.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- The bone marrow microenvironment facilitates cancer cell evasion of therapy, contributing to disease persistence and relapse.
- Dormant micrometastases are implicated in cancer recurrence, but the distinction between cancer stem cells and those with limited metastatic potential remains unclear.
- Bisphosphonates are established treatments for malignant bone disease and bone loss associated with cancer therapy.
Purpose of the Study:
- To review preclinical and clinical studies on bisphosphonates' anticancer activities.
- To explore how bisphosphonates modify the bone marrow microenvironment to inhibit cancer cell survival.
- To summarize the direct and indirect anticancer effects of bisphosphonates on tumor cells and their microenvironment.
Main Methods:
- Literature review of preclinical and early clinical studies.
- Analysis of bisphosphonate mechanisms of action.
- Examination of clinical outcomes in various cancer types.
Main Results:
- Bisphosphonates demonstrate direct and indirect anticancer activities.
- Zoledronic acid improved survival in adjuvant breast cancer, multiple myeloma, and other advanced cancers.
- Antiresorptive therapy delayed bone metastases in prostate cancer.
Conclusions:
- Altering the bone marrow microenvironment is a key strategy to prevent cancer recurrence.
- Bisphosphonates offer potential anticancer benefits by targeting both tumor cells and their microenvironment.
- Further research is ongoing to elucidate the full anticancer potential of bisphosphonates and related agents.
More Related Videos
11:47A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Stabilize Microtubules
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules
Cancer Prevention
Some...